<DOC>
	<DOCNO>NCT00541905</DOCNO>
	<brief_summary>The aim study confirm efficacy safety NT 201 ( Xeomin® , also know IncobotulinumtoxinA ) one injection session determine efficacy safety profile duration treatment effect NT 201 long-term treatment repeat injection session .</brief_summary>
	<brief_title>Daily Dystonia Practice - A Trial Investigate NT 201 , Duration Treatment Effect After One Injection Session Long-term Treatment Cervical Dystonia</brief_title>
	<detailed_description />
	<mesh_term>Dystonia</mesh_term>
	<mesh_term>Dystonic Disorders</mesh_term>
	<mesh_term>Torticollis</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>Toronto Western Spasmodic Torticollis Rating Scale ( TWSTRS ) total score baseline &gt; / = 25 TWSTRS severity score &gt; / = 10 TWSTRS disability score &gt; / = 3 Patients must stable dose medication For pretreated patient : Source documentation last two consecutive injection session botulinum neurotoxin type A stable treatment response directly prior trial entry For pretreated patient : At least 10 week must pass last injection session botulinum neurotoxin type A cervical dystonia time baseline visit . For pretreated patient : The recent injection session botulinum neurotoxin cervical dystonia must dose ≤ 300 unit Botox® Xeomin® , ≤ 1,200 unit Dysport® . Age &gt; / = 18 &lt; 76 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>